Endothelin-1 production and its involvement in cardiovascular diseases

Yakugaku Zasshi

Volumn 127, Issue 9, 2007, Pages 1319-1329

  Ohkita, Mamoru ^a   Takaoka, Masanori ^a   Matsumura, Yasuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Acute renal failure; Endothelin; Nitric oxide; Nuclear factor kappa B; Salt sensitive hypertension

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 27 O [3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY]MYRICERONE; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 [4 [3 (3 METHOXY 5 METHYL 2 PYRAZINYLSULFAMOYL) 2 PYRIDYL]PHENYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 4 TERT BUTYL N [6 (2 HYDROXYETHOXY) 5 (3 METHOXYPHENOXY) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; A 182086; ALPHA [[1 BUTYL 5 [2 [(2 CARBOXYPHENYL)METHOXY] 4 METHOXYPHENYL] 1H PYRAZOL 4 YL]METHYLENE] 6 METHOXY 1,3 BENZODIOXOLE 5 PROPANOIC ACID; ATRASENTAN; BOSENTAN; BQ 610; CLAZOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); D 142893; DARUSENTAN; EMD 122946; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRL 2500; J 104121; J 104131; K 8794; L 754142; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N [6 [2 (5 BROMO 2 PYRIMIDINYLOXY)ETHOXY] 5 (4 METHYLPHENYL) 4 PYRIMIDINYL] 4 (2 HYDROXY 1,1 DIMETHYLETHYL)BENZENESULFONAMIDE; PD 176856; RECEPTOR SUBTYPE; RES 701 1; SB 247083; SITAXSENTAN; TAK 044; TEZOSENTAN; TRANSCRIPTION FACTOR; TTA 788; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 598;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; DNA BINDING; GENE EXPRESSION; HEART MUSCLE ISCHEMIA; HYPERTENSION; IN VIVO STUDY; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; RAT; REVIEW; STRESS;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; KIDNEY FAILURE, ACUTE; NF-KAPPA B; NITRIC OXIDE; RECEPTOR, ENDOTHELIN A;

EID: 34548448496     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.127.1319     Document Type: Review

References (42)

1. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T., Nature, 332, 411-415 (1988).
2. Kitazumi K., Tasaka K., Biochem. Pharmacol., 46, 455-464 (1993).
3. Marsden P. A., Brenner B. M., Am. J. Physiol., 262, C854-C861 (1992).
4. Murata S., Matsumura Y., Takada K., Asai Y., Takaoka M., Morimoto S., J. Pharmacol. Exp. Ther., 274, 1524-1530 (1995).
5. Miyauchi T., Masaki T., Annu. Rev. Physiol., 61, 391-415 (1999).
6. Sen R., Baltimore D., Cell, 46, 705-716 (1986).
7. Tak P. P., Firestein G. S., J. Clin. Invest., 107, 7-11 (2001).
8. Tedgui A., Mallat Z., Circ. Res., 88, 877-887 (2001).
9. Ohkita M., Takaoka M., Kobayashi Y., Itoh E., Uemachi H., Matsumura Y., Jpn. J. Pharmacol., 88, 197-205 (2002).
10. Ohkita M., Takaoka M., Shiota Y., Nojiri R., Sugii M., Matsumura Y., Jpn. J. Pharmacol., 89, 81-84 (2002).
11. Okamoto H., Takaoka M., Ohkita M., Itoh M., Nishioka M., Matsumura Y., Eur. J. Pharmacol., 350, R11-R12 (1998).
12. Takaoka M., Itoh M., Okamoto H., Ohkita M., Matsumura Y., Curr. Top. Pharmacol., 5, 99-107 (2000).
13. Takaoka M., Itoh M., Hayashi S., Kuro T., Matsumura Y., Eur. J. Pharmacol., 384, 43-46 (1999).
14. Takaoka M., Itoh M., Kohyama S., Shibata A., OhkitaM., Matsumura Y., J. Cardiovasc. Pharmacol., 36 (Suppl. 1), S225-S227 (2000).
15. Itoh M., Takaoka M., Shibata A., Ohkita M., Matsumura Y., J. Pharmacol. Exp. Ther., 298, 501-507 (2001).
16. Takaoka M., Kobayashi Y., Yuba M., Ohkita M., Matsumura Y., Eur. J. Pharmacol., 424, 121-129 (2001).
17. Takaoka M., Ohkita M., Itoh M., Kobayashi Y., Okamoto H., Matsumura Y., Clin. Exp. Pharmacol. Physiol., 28, 466-468 (2001).
18. Takaoka M., Ohkita M., Kobayashi Y., Yuba M., Matsumura Y., Clin. Exp. Pharmacol. Physiol., 29, 189-194 (2002).
19. Matsumura Y., Nishiura M., Deguchi S., Hashimoto N., Ogawa T., Seo R., J. Pharmacol. Exp. Ther., 287, 1084-1091 (1998).
20. Kurata H., Takaoka M., Kubo Y., Katayama T., Tsutsui H., Takayama J., Matsumura Y., J. Cardiovasc. Pharmacol., 44 (Suppl. 1), S455-S458 (2004).
21. Ohkita M., Takaoka M., Shiota Y., Nojiri R., Matsumura Y., Clin. Sci., 103 (Suppl. 48), 68S-71S (2002).
22. Ohkita M., Takaoka M., Sugii M., Shiota Y., Nojiri R., Matsumura Y., Eur. J. Pharmacol., 472, 159-164 (2003).
23. Goto K., Hama H., Kasuya Y., Jpn. J. Pharmacol., 72, 261-290 (1996).
24. Lariviere R., Day R., Schiffrin E. L., Hypertension, 21, 916-920 (1993).
25. Matsumura Y., Hashimoto N., Taira S., Kuro T., Kitano R., Ohkita M., Opgenorth T. J., Takaoka M., Hypertension, 33, 759-765 (1999).
26. Matsumura Y., Kuro T., Kobayashi Y., Konishi F., Takaoka M., Wessale J. L., Opgenorth T. J., Gariepy C. E., Yanagisawa M., Circulation, 102, 2765-2773 (2000).
27. Giardina J. B., Green G. M., Rinewalt A. N., Granger J. P., Khalil R. A., Hypertension, 37, 516-523 (2001).
28. Rothermund L., Luckert S., Kossmehl P., Paul M., Kreutz R., Hypertension, 37, 275-280 (2001).
29. Gariepy C. E., Ohuchi T., Williams S. C., Richardson J. A., Yanagisawa M., J. Clin. Invest., 105, 925-933 (2000).
30. Gallego M. S., Ling B. N., Am. J. Physiol., 271, F451-F460 (1996).
31. Ohkita M., Wang Y., Nguyen N. D., Tsai Y. H., Williams S. C., Wiseman R. C., Killen P. D., Li S., Yanagisawa M., Gariepy C. E., Hypertension, 45, 940-946 (2005).
32. Li J. S., Lariviere R., Schiffrin E. L., Hypertension, 24, 183-188 (1994).
33. Takaoka M., Kuro T., Matsumura Y., Drug News Perspect., 13, 141-146 (2000).
34. Kuro T., Kohnou K., Kobayashi Y., Takaoka M., Opgenorth T. J., Wessale J. L., Matsumura Y., Jpn. J. Pharmacol., 82, 307-316 (2000).
35. Matsumura Y., Kuro T., Kobayashi Y., Umekawa K., Ohashi N., Takaoka M., Jpn. J. Pharmacol., 84, 16-24 (2000).
36. Yamashita J., Itoh M., Kuro T., Kobayashi Y., OgataM., TakaokaM., Matsumura Y., J. Pharmacol. Exp. Ther., 296, 412-419 (2001).
37. Hu J., Discher D. J., Bishopric N. H., Webster K. A., Biochem. Biophys. Res. Commun., 245, 894-899 (1998).
38. Wilhelm S. M., Simonson M. S., Robinson A. V., Stowe N. T., Schulak J. A., Kidney Int., 55, 1011-1018 (1999).
39. Ruschitzka F., Shaw S., Gygi D., Noll G., Barton M., Luscher T. F., J. Am. Soc. Nephrol., 10, 953-962 (1999).
40. Takaoka M., Yuba M., Fujii T., Ohkita M., Matsumura Y., Clin. Sci., 103 (Suppl. 48), 434S-437S (2002).
41. Shibata Y., Takaoka M., Maekawa D., Kuwahara C., Matsumura Y., J. Cardiovasc. Pharmacol., 44 (Suppl. 1), S459-S461 (2004).
42. Yamashita J., Ogata M., Itoh M., Yamasowa H., Shimeda Y., Takaoka M., Matsumura Y., J. Cardiovasc. Pharmacol., 42, 419-427 (2003).